Schedules of Controlled Substances: Temporary Placement of 7- Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I 2026-20943 | Proposed rule | Oct 14 |
Schedules of Controlled Substances: Temporary Placement of MGM-15 and MGM-16 in Schedule I 2026-20942 | Proposed rule | Oct 14 |
Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products 2026-20757 | Final rule | Oct 9 |
Schedules of Controlled Substances: Placement of O-Desmethyltramadol in Schedule I; Correction 2026-20748 | Final rule | Oct 9 |
Extension of Reexportation Period. 2026-20084 | Proposed rule | Oct 1 |
Schedules of Controlled Substances: Placement of 4-Hydroxy-N,N-Diisopropyltryptamine (4-OH-DiPT), 5-Methoxy-alpha-Methyltryptamine (5-MeO-AMT), 5-Methoxy-N-Methyl-N-Isopropyltryptamine (5-MeO-MiPT), 5-Methoxy-N,N-Diethyltryptamine (5-MeO-DET), and N,N-Diisopropyltryptamine (DiPT) Into Schedule I 2026-19400 | Proposed rule | Sep 23 |
Schedules of Controlled Substances: Placement of Diphenidine in Schedule I 2026-19231 | Final rule | Sep 21 |
Schedules of Controlled Substances: Placement of Cipepofol in Schedule IV 2026-17536 | Final rule | Aug 27 |
Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act 2026-17531 | Final rule | Aug 27 |
Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I 2026-17429 | Final rule | Aug 26 |
Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I 2026-16413 | Final rule | Aug 12 |
Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V 2026-16375 | Proposed rule | Aug 11 |
Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical 2026-15624 | Proposed rule | Aug 3 |
Designation of Phenethyl Halides as List I Chemicals 2026-13825 | Proposed rule | Jul 9 |
Schedules of Controlled Substances: Placement of Tianeptine in Schedule I 2026-13821 | Proposed rule | Jul 8 |
Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I 2026-13581 | Proposed rule | Jul 6 |
Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I 2026-13580 | Proposed rule | Jul 6 |
Schedules of Controlled Substances: Temporary Placement of 5,6- Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act 2026-13364 | Proposed rule | Jul 1 |
Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I 2026-12654 | Final rule | Jun 24 |
Schedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correction 2026-12653 | Final rule | Jun 24 |
Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment 2026-11526 · significant | Final rule | Jun 9 |
Schedules of Controlled Substances: Placement of Diphenidine in Schedule I 2026-10380 | Proposed rule | May 26 |
Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products 2026-10379 | Proposed rule | May 26 |
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I 2026-10253 | Final rule | May 22 |
Revision of Applications for Manufacturing and Procurement Quotas 2026-10128 · significant | Proposed rule | May 20 |
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I 2026-09566 | Final rule | May 13 |
Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance 2026-08595 | Final rule | May 4 |
Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I 2026-08517 | Final rule | May 1 |
Schedules of Controlled Substances: Rescheduling of Marijuana; Withdrawal 2026-08178 | Proposed rule | Apr 28 |
Schedules of Controlled Substances: Rescheduling of Marijuana 2026-08177 | Proposed rule | Apr 28 |
Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements 2026-08176 | Final rule | Apr 28 |
Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I 2026-08104 | Final rule | Apr 24 |
Designation of P2P Methyl Glycidic Acid as a List I Chemical 2026-06523 | Final rule | Apr 3 |
Registering Emergency Medical Services Agencies Under the Protecting Patient Access to Emergency Medications Act of 2017 C1-2026-02288 · significant | Final rule | Apr 1 |
Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I 2026-05618 | Final rule | Mar 23 |
Ordering Schedule I and II Controlled Substances Using DEA Form 222; Technical Amendments 2026-05482 | Final rule | Mar 20 |
Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I 2026-05064 | Final rule | Mar 16 |
Designation of Propionyl Chloride as a List I Chemical 2026-04657 | Final rule | Mar 10 |
Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act 2026-04112 | Final rule | Mar 2 |
Registering Emergency Medical Services Agencies Under the Protecting Patient Access to Emergency Medications Act of 2017 2026-02288 · significant | Final rule | Feb 5 |
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I 2026-00954 | Proposed rule | Jan 20 |
Definition of “Cannabimimetic Agents” and Assignment of an Administration Controlled Substances Code Number for All “Cannabimimetic Agents” 2026-00907 | Final rule | Jan 20 |
Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I 2026-00633 | Final rule | Jan 15 |
Schedules of Controlled Substances: Placement of N-Pyrrolidino Metonitazene and N-Pyrrolidino Protonitazene in Schedule I 2026-00362 | Final rule | Jan 12 |
Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications 2025-24123 · significant | Final rule | Dec 31, 2025 |
Schedules of Controlled Substances: Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I 2025-23717 | Final rule | Dec 23, 2025 |
Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I 2025-22963 | Proposed rule | Dec 16, 2025 |
Schedules of Controlled Substances: Extension of Temporary Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I of the Controlled Substances Act 2025-22960 | Final rule | Dec 16, 2025 |
Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I 2025-22763 | Proposed rule | Dec 15, 2025 |
Schedules of Controlled Substances: Extension of Temporary Placement of MDMB-4en-PINACA in Schedule I of the Controlled Substances Act 2025-22540 | Final rule | Dec 11, 2025 |
Schedules of Controlled Substances: Extension of Temporary Placement of CUMYL-PEGACLONE in Schedule I of the Controlled Substances Act 2025-22496 | Final rule | Dec 11, 2025 |
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I 2025-22495 | Proposed rule | Dec 11, 2025 |
Schedules of Controlled Substances: Placement of 4-Chloromethcathinone in Schedule I 2025-20004 | Final rule | Nov 17, 2025 |
Schedules of Controlled Substances: Temporary Placement of Ethyleneoxynitazene, Methylenedioxynitazene, 5-Methyl Etodesnitazene, N-Desethyl Etonitazene, N-Desethyl Protonitazene, N,N-Dimethylamino Etonitazene, and N-Pyrrolidino Isotonitazene in Schedule I 2025-19542 | Final rule | Oct 15, 2025 |
Designation of P2P Methyl Glycidic Acid as a List I Chemical 2025-19384 | Proposed rule | Oct 2, 2025 |
Specific Listing for 1-boc-4-piperidone, a Currently Controlled List I Chemical 2025-19349 | Final rule | Oct 2, 2025 |
Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I 2025-19348 | Proposed rule | Oct 2, 2025 |
Controlled Substances Ordering System (CSOS) Modernization 2025-19325 | Final rule | Oct 2, 2025 |
Requiring Online Submission of Applications for and Renewals of DEA Registration: Technical Correction 2025-19292 | Final rule | Oct 2, 2025 |
Schedules of Controlled Substances: Placement of Seven Specific Fentanyl-Related Substances in Schedule I 2025-18103 | Final rule | Sep 18, 2025 |
Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I 2025-15566 | Final rule | Aug 15, 2025 |
Specific Listing for Dipentylone, a Currently Controlled Schedule I Substance 2025-15177 | Final rule | Aug 8, 2025 |
Schedules of Controlled Substances: Extension of Temporary Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act 2025-14037 | Final rule | Jul 25, 2025 |
Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act 2025-14022 | Proposed rule | Jul 25, 2025 |
Schedules of Controlled Substances: Temporary Placement of Seven Benzimidazole-Opioids in Schedule I 2025-11462 | Proposed rule | Jun 26, 2025 |
Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-[1-(3-methoxyphenyl)cyclohexyl]piperidine) in Schedule I 2025-10503 | Proposed rule | Jun 10, 2025 |
Schedules of Controlled Substances: Placement of Three Specific Fentanyl-Related Substances in Schedule I 2025-10372 | Proposed rule | Jun 10, 2025 |
Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I; Correction 2025-09989 | Final rule | Jun 3, 2025 |
Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I 2025-09988 | Proposed rule | Jun 3, 2025 |
Designation of Propionyl Chloride as a List I Chemical 2025-09983 | Proposed rule | Jun 3, 2025 |
Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients 2025-05007 · significant | Final rule | Mar 24, 2025 |
Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients 2025-02793 · significant | Final rule | Feb 19, 2025 |
Special Registrations for Telemedicine and Limited State Telemedicine Registrations 2025-01099 · significant | Proposed rule | Jan 17, 2025 |
Expansion of Buprenorphine Treatment via Telemedicine Encounter 2025-01049 · significant | Final rule | Jan 17, 2025 |
Continuity of Care via Telemedicine for Veterans Affairs Patients 2025-01044 · significant | Final rule | Jan 17, 2025 |
Schedules of Controlled Substances: Extension of Temporary Placement of Seven Specific Fentanyl-Related Substances in Schedule I of the Controlled Substances Act 2024-31130 | Final rule | Dec 30, 2024 |
Schedules of Controlled Substances: Placement of Seven Specific Fentanyl-Related Substances in Schedule I 2024-30798 | Proposed rule | Dec 30, 2024 |
Schedules of Controlled Substances: Placement of 4-Chloromethcathinone in Schedule I 2024-30359 | Proposed rule | Dec 30, 2024 |
Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications 2024-27018 · significant | Final rule | Nov 19, 2024 |
Possible Control of Phenethyl Bromide as a List I Chemical 2024-24616 | Proposed rule | Oct 28, 2024 |
Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I 2024-24635 | Final rule | Oct 25, 2024 |
Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I 2024-24083 | Final rule | Oct 22, 2024 |
Schedules of Controlled Substances: Temporary Placement of N-Pyrrolidino Metonitazene and N-Pyrrolidino Protonitazene in Schedule I 2024-21058 | Proposed rule | Sep 17, 2024 |
Schedules of Controlled Substances: Rescheduling of Marijuana 2024-19370 · significant | Proposed rule | Aug 29, 2024 |
Schedules of Controlled Substances: Placement of Zuranolone in Schedule IV 2024-18087 | Final rule | Aug 14, 2024 |
Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I 2024-16391 | Final rule | Jul 29, 2024 |
Announcement of Stayed Hearing: Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I 2024-12504 | Proposed rule | Jun 7, 2024 |
Schedules of Controlled Substances: Rescheduling of Marijuana 2024-11137 | Proposed rule | May 21, 2024 |
Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I 2024-07694 | Proposed rule | Apr 11, 2024 |
Schedules of Controlled Substances: Extension of Temporary Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I of the Controlled Substances Act 2024-07689 | Final rule | Apr 11, 2024 |
Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino Etonitazene, and Protonitazene in Schedule I 2024-07684 | Final rule | Apr 11, 2024 |
Announcement of Hearing: Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) inSchedule I 2024-07473 | Proposed rule | Apr 9, 2024 |
Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I 2024-05543 | Final rule | Mar 15, 2024 |
Conforming Amendment Regarding the Veterinary Medicine Mobility Act of 2014 2024-02322 · significant | Final rule | Feb 8, 2024 |
Controlled Substance Destruction Alternatives to Incineration; Extension of Comment Period 2023-28964 | Proposed rule | Jan 3, 2024 |